[18F] 3-deoxy-3′-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[ 18F]-fluoro-2-deoxy-o-glucose positron emission tomography in the workup of suspicious central focal lesions?

Journal of Thoracic and Cardiovascular Surgery

Volumn 127, Issue 4, 2004, Pages 1093-1099

  Halter, Gisela ^a   Buck, A K ^a   Schirrmeister, H ^a   Wurziger, I ^a   Liewald, F ^a   Glatting, G ^a   Neumaier, B ^a   Sunder Plassmann, L ^a   Reske, S N ^a   Hetzel, M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEOXY 3' FLUOROTHYMIDINE F 18; 3' FLUOROTHYMIDINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; LUNG CARCINOMA; LUNG TUMOR; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LABORATORY DIAGNOSIS; LUNG NON SMALL CELL CANCER; LYMPH NODE; MIDDLE AGED; MULTIPLE CANCER; PATHOLOGY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, BRONCHOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FALSE POSITIVE REACTIONS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1842453900     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.09.003     Document Type: Article

References (30)

1. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556-65.
2. Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med. 1996:23:204-6.
3. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage 1 disease. Radiology. 2000;215:886-890.
4. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914-24.
5. 18F]FDG positron emission tomography (PET). Thorax. 1997;52:438-41.
6. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose (FDG-PET) in lung tumors as a base for discussion of the German Consensus Conference on PET in Oncology. Pneumologie. 2001:55:367-77.
7. Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-604.
8. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001:19:111-8.
9. Liewald F, Grosse S, Storck M, et al. How useful is positron emission tomography for lymph node staging in non small-cell lung cancer? Thorac Cardiovasc Surg. 2000;48:93-6.
10. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886-95.
11. Patz EF Jr. Connolly J, Hemdon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol. 2000;174:769-74.
12. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-6.
13. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-44.
14. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994;191:371-7.
15. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8.
16. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-181FLT and positron emission tomography. Nat Med. 1998;4:1334-6.
17. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidin kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-7.
18. Buck AK, Schirrmeister H, Hetzel M, et al. 3-Deoxy-3-(18F) fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331-4.
19. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988:96:440-7.
20. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′ -[(18)F] [(18)F]fluorothymidine: [(18)F] [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27(2):143-56.
21. Schmidlin P. Iterative algorithms for emission tomography [in German]. Nuklearmedizin. 1990;3:155-8.
22. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2. and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15:2456-66.
23. Hallett WA, Marsden PK, Cronin BF, O'Doherty MJ. Effect of corrections for blood glucose and body size on[18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med. 2001;28:919-22.
24. Harpole DH. Prognostic issues in non-small cell lung cancer. Chest. 1995;107(suppl):S267-9.
25. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85-92.
26. Blau I, Elstner E, Waechter M. Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3′-deoxy-3′-fluorothymidine in comparison to 3′-azido-3′-deoxytymidine. Blut. 1989;59:455-7.
27. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-T-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-18.
28. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis. 1994;170:1394-403.
29. Machulla HJ, Blocher A, Kuntzsch M. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F] [18F]fluorothymidine ([18F] [18F]FLT). J Radioanal Nucl Chem. 2000;24:843-846.
30. Wilson I, Chatterjee S, Wolf W. Synthesis of 3′-fluoro-3′ -deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. J Fluorine Chem. 1991:55:283-289.